Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCA101 Monotherapy and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT04429542Phase 1Recruiting
- Sponsor
- Bicara Therapeutics
- Start
- Jun 2020
- Primary completion
- Oct 2027
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of ficerafusp alfa in solid tumor, head and neck squamous cell carcinoma (HNSCC), anal canal squamous cell carcinoma (SCCA) and 3 more (2 arms), sponsored by Bicara Therapeutics. Primary endpoints: Incidence and severity of Adverse Events and Serious Adverse Events at 24 months and Incidence of Dose Limiting Toxicities at 21 days. Started Jun 2020; status: recruiting.
02
Drugs
ficerafusp alfa
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)anal canal squamous cell carcinoma (SCCA)cutaneous squamous cell carcinoma (cSCC)squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT04429542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04429542.